FDA Clears Onclarity HPV At-Home Self-Collection. The Cervical Screening Landscape Just Widened Again.

Originally surfaced May 14, 2026, drawing on the April 2026 FDA clearance.

In April 2026, the FDA cleared Onclarity's HPV Self-Collection Kit for at-home cervical cancer screening. This follows the May 2025 FDA approval of Teal Health's Teal Wand, which was the first at-home HPV self-collection kit on the U.S. market and which reached availability in all 50 states by January 2026. The Onclarity clearance means at-home HPV screening is no longer a single-product category.

The Health Resources and Services Administration also updated its Women's Preventive Services Guidelines in January 2026 to recommend self-administered HPV tests as an option for women aged 30 to 65 at average risk. Coverage under that guideline is expected to begin January 1, 2027.

Why this matters

The big policy bet behind HPV self-collection is that meaningful numbers of eligible women never get cervical cancer screening through the clinical pathway. Some of that is discomfort with the speculum exam. Some of it is access. Some of it is the simple friction of getting a clinician appointment for a screening test that, especially for HPV-negative women under the every-five-year cadence, is genuinely rare.

An at-home self-collected sample, mailed to a CLIA-certified lab, can be a reasonable substitute for the collection step in primary HPV screening. It is not a substitute for the larger clinical pathway when a result is positive or when symptoms appear.

What HPV testing is and is not

HPV testing identifies high-risk strains of human papillomavirus that drive most cervical cancers. A positive HPV result is not a cancer diagnosis. It is a signal that further follow-up is warranted, typically including colposcopy, repeat HPV testing, or other clinical evaluation as a clinician judges.

For a standalone HPV check, LabTestSuperstore's HPV test is available. For people whose sexual-health context is broader than HPV alone, the Basic STD Panel and Expanded STD Panel cover other commonly screened-for infections; those do not include HPV by default. For background on related symptoms, see our STD symptoms page.

What this hot take is not saying

Nothing in this commentary is medical advice. The April 2026 Onclarity clearance is a specific FDA action on a specific test sold by a specific company, and a self-pay HPV test ordered through any direct-to-consumer site is a different product. Anyone with a positive HPV result, an abnormal Pap result, or symptoms should be in care with a clinician, not relying on a screening test alone to decide what to do next.